[A20-90] Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 15.01.2021
Commission awarded on 15.10.2020 by the Federal Joint Committee (G-BA).
Muscles, bones and joints
Adults with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more DMARDs
First-time therapy with bDMARDs or tsDMARDs indicated: in combination with MTX, hint of minor added benefit. Other constellations: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A21-155||Filgotinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V||Commission completed|